Sammy Siada, DO
Vascular Surgery · Fresno, CANPI 1538402581
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (32.8%), speaking fees and grants — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Shockwave Medical, Inc at 30.1% of the total. Reporting peaked in 2019 at $7,925 and has fallen 87.9% since, to $962 in 2025.
Across 151 payments — averaging $171.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$8K
- Medtronic$7K
- Penumbra, Inc.$3K
- W. L. Gore & Associates, Inc.$2K
- Bolton Medical Inc$2K
- Abbott$1K
- plus $3K from 13 others
Across 9 payments — averaging $4386.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bolton Medical Inc$39K
What the payments were for
- Consulting fees$8503%
- Speaking & faculty fees$7,10027%
- Grants$5,47521%
- Travel & lodging$3,86515%
- Food & beverage$8,50033%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 15 | $7,804 |
| Medtronic(2 entities) | 37 | $7,390 |
| Penumbra, Inc. | 15 | $2,954 |
| W. L. Gore & Associates, Inc. | 20 | $1,926 |
| Bolton Medical Inc | 17 | $1,587 |
| Abbott | 5 | $1,264 |
| Cook Medical LLC | 10 | $1,087 |
| Silk Road Medical, Inc. | 9 | $1,080 |
| Boston Scientific | 3 | $168 |
| Johnson & Johnson(2 entities) | 3 | $164 |
| Humacyte Global, Inc. | 1 | $145 |
| E.r. Squibb & Sons, L.L.C. | 4 | $83 |
| Lemaitre Vascular, Inc. | 2 | $55 |
| Inari Medical, Inc. | 2 | $47 |
| AstraZeneca | 2 | $38 |
| Cardiovascular Systems Inc. | 3 | $34 |
| Smith+Nephew | 1 | $28 |
| Cordis US CORP. | 1 | $20 |
| KCI USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$7,365
- Endurant$5,244
- RUBY Coil$1,739
- GORE TAG Thoracic Endoprosthesis$1,231
- ENROUTE Transcarotid Neuroprotection System$1,106
- HawkOne$883
- XACT$850
- ENROUTE Transcarotid Stent$839
- Grafts$803
- Indigo System$657
- ENHANCE Transcarotid Peripheral Access Kit$422
- ENROUTE .014 Guidewire$312
- Relay Grafts$266
- Penumbra Coil 400$239
- VenaSeal$174
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$157
- Supera peripheral stent system$149
- Vascular Lithotripsy$146
- Symvess$145
- Accent Pacemaker$141
How this compares
$25,890 in reported general payments places this provider in the 85th percentile of 519 vascular surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 37 | $28,027 |
| Cilostazol | 21 | $235 |
| ClopidogrelClopidogrel Bisulfate | 27 | $202 |
| Gabapentin | 18 | $153 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 47 | $129 |
| Alprazolam | 52 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $164 | $28,02737 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 519 vascular surgery providers in California.
Other vascular surgery in Fresno
- Leigh Ann ObanionFresno$469K
- Randall SternFresno$70K
- Son DuongFountain Valley$503K
- Venita ChandraPalo Alto$488K
- Sukgu HanLos Angeles$477K
- Trevor DerderianRancho Mirage$359K
- Karthikeshwar KasirajanPalo Alto$349K
- Johnathon RolloLos Angeles$337K
- Melissa LojaFairfield$272K
- Jason LeePalo Alto$228K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.